Research Activity – Page 51

Addex Therapeutics’ Phase II Epilepsy Drug in Partnership with J&J Fails to Meet Endpoints

12 months ago talkbio0Tagged Clinical, development aspects, drug candidate, Epilepsy, J&J, Phase 2 Clinical Trials

Addex Therapeutics, J&J, Phase II trial, epilepsy, drug candidate, clinical endpoints, future development.

Sanofi Eyes COPD Treatment as Major Growth Driver for Dupixent, Says CEO

12 months ago talkbio0Tagged Asthma, CEO, Chronic Obstructive Airway Disease, Clinical Trials, Dermatitis, Atopic, Dupixent, expansion, growth pillar, Immunology, sanofi

Sanofi, Dupixent, COPD, growth pillar, immunology, CEO, treatment, expansion, clinical trials, asthma, atopic dermatitis.

Regeneron Pharmaceuticals Expands Gene Editing Capabilities with Mammoth Biosciences Partnership

12 months ago talkbio0Tagged Biotechnology, Clustered Regularly Interspaced Short Palindromic Repeats, development aspects, Gene Modification, Genetic Research, Health care facility, Mammoth Biosciences, Partnership, Regeneron

Regeneron, Mammoth Biosciences, gene editing, CRISPR, partnership, biotechnology, healthcare, pharmaceuticals, genetic research, therapeutic development.

Endeavor’s $132.5 Million Funding Accelerates Fibrotic Lung and Solid Tumor Therapeutic Development

1 year ago talkbio0Tagged development aspects, Endeavor, fibrotic, healthcare innovation, Lung, Medical Research activity, Solid Neoplasm

Endeavor, funding, fibrotic lung, solid tumors, therapeutic development, medical research, healthcare innovation.

Biogen’s Leqembi Gains Momentum: A Steady Pace in Market Growth

1 year ago talkbio0Tagged Alzheimer 's disease, Approved, Biogen, Clinical Trials, Growth, Health care facility, Leqembi, Market, Neurology speciality, United States Food and Drug Administration

Biogen, Leqembi, Alzheimer’s disease, clinical trials, FDA approval, market growth, steady pace, neurology, healthcare, pharmaceuticals.

Day One Outshines Novartis: FDA Approves Ojemda for Wider Pediatric Brain Tumor Treatment

1 year ago talkbio0Tagged Brain Neoplasms, Cancer Therapeutic Procedure, Clinical Trials, Drug Industry, Novartis, Ojemda, Pediatric brand name, United States Food and Drug Administration

Day One, Novartis, FDA, Ojemda, pediatric brain tumor, cancer treatment, clinical trials, pharmaceutical industry.

Xaira: The Billion-Dollar AI-Powered Drug Discovery Startup Revolutionizing Healthcare

1 year ago talkbio0Tagged AI, Artificial Intelligence, Biotechnology, Drug Discovery, Health care facility, startup, Xaira

Xaira, AI, drug discovery, healthcare, startup, funding, billion-dollar, revolutionizing, pharmaceuticals, biotechnology.

Revolutionizing Research and Development: Xaira Unveils AI-Driven Platform with $1B Funding and Former Genentech Leaders

1 year ago talkbio0Tagged AI-Powered Xaira, Artificial Intelligence, Biotechnology, cell transformation, Genentech executives, innovation, R&D, research, Surgical advancement - action

AI-Powered Xaira, $1B funding, Genentech executives, R&D transformation, biotechnology innovation, artificial intelligence in research, life sciences advancement.